Breaking News, Collaborations & Alliances

Ipsen, Inspiration Restructure Hemophilia Pact

Ipsen gains rights in key territories, Inspiration to handle worldwide development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ipsen and Inspiration Biopharmaceuticals have restructured their 2010 strategic partnership for the development and commercialization of Inspiration’s recombinant product portfolio: OBI-1, a recombinant porcine factor VIII (rpFVIII) for the treatment of acquired hemophilia A and congenital hemophilia A, and IB1001, a recombinant factor IX (rFIX) for the treatment and prevention of bleeding in patients with hemophilia B.   Under the new agreement, Ipsen gains commercial rights in key territories ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters